This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
by Zacks Equity Research
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
by Zacks Equity Research
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
by Zacks Equity Research
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
Nektar (NKTR) Up on Positive New Data From Eczema Study
by Zacks Equity Research
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Top-Ranked Stocks With Rising P/E for Solid Returns
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
by Zacks Equity Research
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
by Zacks Equity Research
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
by Kinjel Shah
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.